Continuous infusion of recombinant activated factor VII during caesarean section delivery in a patient with congenital factor VII deficiency.
Recombinant activated factor VII (rFVIIa) can be used as an alternative therapy in patients with FVII deficiency. However, as the drug has a very short half-life, continuous infusion could be a meaningful administration modality. We report the case of a 30-year-old woman with moderate FVII deficiency and human immunodeficiency virus infection who underwent a caesarean section delivery. She was treated with a continuous infusion of rFVIIa and did not suffer any bleeding complication. The continuous infusion of rFVIIa was a safe and effective therapeutic approach for our patient, maintaining her levels of FVII:C and avoiding bleeding during caesarean section and afterwards.
Jiménez-Yuste
V
V
Hemophilia Centre, Department of Hematology, La Paz University Hospital, Madrid, Spain.
Villar
A
A
Morado
M
M
Canales
M
M
Hernández
M C
MC
Sanjurjo
M J
MJ
Quintana
M
M
Hernández-Navarro
F
F
D000328:Adult; D016063:Blood Loss, Surgical / Q000517:prevention & control; D002585:Cesarean Section / Q000009:adverse effects / Q000379:methods*; D005167:Factor VII / Q000008:administration & dosage*; D005168:Factor VII Deficiency / Q000150:complications* / Q000151:congenital* / Q000188:drug therapy*; D005260:Female; D015658:HIV Infections; D006470:Hemorrhage / Q000188:drug therapy / Q000517:prevention & control; D006801:Humans; D007263:Infusions, Parenteral; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000188:drug therapy; D011994:Recombinant Proteins / Q000008:administration & dosage
D011994:Recombinant Proteins; D005167:Factor VII